| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8274848 | Journal of the Neurological Sciences | 2016 | 7 Pages |
Abstract
Alemtuzumab demonstrated a broad treatment effect in improving preexisting disability. These findings may influence treatment decisions in patients with early, active relapsing-remitting MS displaying neurological deficits. ClinicalTrials.gov Identifier NCT00050778.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Edward J. Fox, Daniel Wynn, Alasdair J. Coles, Jeffrey Palmer, David H. Margolin, on behalf of CAMMS223 Investigators on behalf of CAMMS223 Investigators,